ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2003
Substance P Acts through local circuits within the rat dorsal raphe nucleus to alter serotonergic neuronal activity.
Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 60 citations in OpenAlex.
- Imaging drugs with and without clinical analgesic efficacy.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2011Trial
- Neurokinin receptor antagonists for vasomotor symptoms: from KNDy neurons to clinical translation.Nature reviews. Endocrinology · 2026Review
- The role of dorsal raphe nucleus neuropeptides in reward and aversion.Frontiers in behavioral neuroscience · 2025Review
- Dorsal raphe organization.Journal of chemical neuroanatomy · 2020Review
- Neurokinin receptors in drug and alcohol addiction.Brain research · 2020Review
- The Hypothalamic-Pituitary-Adrenal Axis and Serotonin Metabolism in Individual Brain Nuclei of Mice with Genetic Disruption of the NK1 Receptor Exposed to Acute Stress.Cellular and molecular neurobiology · 2018Article
- Neuronal connectivity between habenular glutamate-kisspeptin1 co-expressing neurons and the raphe 5-HT system.Journal of neurochemistry · 2015Article
- Conserved expression of the GPR151 receptor in habenular axonal projections of vertebrates.The Journal of comparative neurology · 2015Article
- A group of non-serotonergic cells is CO2-stimulated in the medullary raphé.Neuroscience · 2014Article
- Elevated cerebrospinal fluid 5-hydroxyindoleacetic acid in macaques following early life stress and inverse association with hippocampal volume: preliminary implications for serotonin-related function in mood and anxiety disorders.Frontiers in behavioral neuroscience · 2014Article
- A neurobiological hypothesis of treatment-resistant depression - mechanisms for selective serotonin reuptake inhibitor non-efficacy.Frontiers in behavioral neuroscience · 2014Review
- Microarray analyses reveal novel targets of exercise-induced stress resistance in the dorsal raphe nucleus.Frontiers in behavioral neuroscience · 2013Article
- Review
- Stress-related serotonergic systems: implications for symptomatology of anxiety and affective disorders.Cellular and molecular neurobiology · 2012Review
- Where does a migraine attack originate? In the brainstem.Journal of neural transmission (Vienna, Austria : 1996) · 2012Review
- Kynurenines and headache.Journal of neural transmission (Vienna, Austria : 1996) · 2012Review
- Cortical nNOS neurons co-express the NK1 receptor and are depolarized by Substance P in multiple mammalian species.Frontiers in neural circuits · 2012Article
- Glutamatergic drive of the dorsal raphe nucleus.Journal of chemical neuroanatomy · 2011Review
- Kynurenine metabolites and migraine: experimental studies and therapeutic perspectives.Current neuropharmacology · 2011Article
- Functional topography of midbrain and pontine serotonergic systems: implications for synaptic regulation of serotonergic circuits.Psychopharmacology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Basic and clinical studies suggest that neurokinin 1 (NK1) receptor antagonists have efficacy in the treatment of affective disorders through effects on the dorsal raphe nucleus (DR), a source of forebrain-projecting serotonin (5-HT) neurons that has also been implicated in affective disorders. To investigate the regulation of the DR-5-HT system by NK1 receptors, the effects of substance P (an NK1 agonist) on rat DR neuronal activity were characterized. Most of the DR neurons (83%; n = 47 total) were inhibited by substance P microinfusion into the DR, and in some cases (17%) this was preceded by a brief activation. Pure excitation was observed in a small population of neurons (17%) that were localized in the dorsal DR, where NK1 receptors are most dense. Sendide, a selective NK1 antagonist, attenuated the effects of substance P, indicating that they were mediated by NK1 receptor activation. The selective 5-HT1A antagonist, WAY 100635, administered systemically or into the DR, prevented the inhibitory effects of substance P, implicating DR 5-HT1A receptors in this response. Finally, microinfusion of the excitatory amino acid antagonist, kynurenic acid, into the DR prevented both excitatory and inhibitory effects. The results suggest that NK1 receptor activation in the DR excites a population of 5-HT neurons via glutamatergic transmission. This results in 5-HT release throughout the DR, activation of 5-HT1A receptors, and subsequent inhibition. Interactions between NK1 and 5-HT1A receptors within DR neural networks may contribute to the mechanism of action of novel antidepressants acting at NK1 receptors.
Indexed as
Identifiers
12904475PMC6740675W1483125751What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.